NEW
YORK, July 12, 2024 /PRNewswire/ -- The
global central nervous system (CNS) stimulant drugs
market size is estimated to grow by USD
6.48 billion from 2023-2027, according to Technavio.
The market is estimated to grow at a CAGR of 5.8%
during the forecast period. Rise in incidence of cns
disorders is driving market growth, with a trend
towards increased uptake of new-generation drugs.
However, numerous side effects of drugs poses a
challenge. Key market players include Astellas Pharma Inc., Azurity
Pharmaceuticals Inc., Elite Pharmaceuticals Inc., Hisamitsu
Pharmaceutical Co. Inc., Ironshore, Jazz Pharmaceuticals Plc,
KemPharm Inc., Merck and Co. Inc., Novartis AG, Pfizer Inc., Purdue
Pharma LP, Sanofi SA, Shionogi and Co. Ltd., Takeda Pharmaceutical
Co. Ltd., Teva Pharmaceutical Industries Ltd., Tris Pharma Inc.,
Viatris Inc., and Thermo Fisher Scientific Inc..
Get a detailed analysis on regions, market segments, customer
landscape, and companies- View the snapshot of this
report
Central Nervous
System (CNS) Stimulant Drugs Market Scope
|
Report
Coverage
|
Details
|
Base year
|
2022
|
Historic
period
|
2017 - 2021
|
Forecast
period
|
2023-2027
|
Growth momentum &
CAGR
|
Accelerate at a CAGR of
5.8%
|
Market growth
2023-2027
|
USD 6486.71
million
|
Market
structure
|
Fragmented
|
YoY growth 2022-2023
(%)
|
5.6
|
Regional
analysis
|
North America, Europe,
Asia, and Rest of World (ROW)
|
Performing market
contribution
|
North America at
43%
|
Key
countries
|
US, Canada, UK,
Germany, and China
|
Key companies
profiled
|
Astellas Pharma Inc.,
Azurity Pharmaceuticals Inc., Elite Pharmaceuticals Inc., Hisamitsu
Pharmaceutical Co. Inc., Ironshore, Jazz Pharmaceuticals Plc,
KemPharm Inc., Merck and Co. Inc., Novartis AG, Pfizer Inc., Purdue
Pharma LP, Sanofi SA, Shionogi and Co. Ltd., Takeda Pharmaceutical
Co. Ltd., Teva Pharmaceutical Industries Ltd., Tris Pharma Inc.,
Viatris Inc., and Thermo Fisher Scientific Inc.
|
Market Driver
The Central Nervous System (CNS) stimulant and anti-epileptic
drugs market has witnessed significant advancements over the past
few decades. First-generation anti-epileptic drugs, such as
phenobarbital, ethosuximide, primidone, phenytoin, carbamazepine,
and valproic acid, were commonly used for several years. However,
these drugs were associated with numerous side effects, narrow
therapeutic ranges, and complex pharmacokinetics. During the 1990s
and early 2000s, second-generation anti-epileptic drugs, including
levetiracetam, lamotrigine, pregabalin, topiramate, and gabapentin,
entered the market. Compared to first-generation drugs,
second-generation drugs have fewer side effects and wider
therapeutic ranges. However, their slower adoption into epilepsy
treatment algorithms limits their market share. More recently,
third-generation anti-epileptic drugs, such as rufinamide,
eslicarbazepine, retigabine, and lacosamide, have emerged. These
drugs offer even fewer side effects and broader therapeutic ranges,
leading to a higher uptake. Similarly, in the antipsychotic drug
market, third-generation drugs are gaining popularity over first-
and second-generation drugs for the treatment of schizophrenia and
bipolar disorders. The development of new-generation drugs with
more effective mechanisms of action and fewer side effects is
expected to fuel market growth during the forecast
period.
The Central Nervous System (CNS) stimulant drugs market is
experiencing significant growth, particularly in healthcare
services related to Child & Adolescent Psychiatry, Sleep Apnea,
and Narcolepsy. The American Thoracic Society and Sleep Care Online
are key players in this industry, focusing on senior population and
country-level treatments. Innovators like Independence
Pharmaceuticals are driving the market with cutting-edge solutions.
Projections show an active growth trajectory, with inorganic growth
strategies being prioritized. Financial details indicate steady
revenue growth, fueled by success factors such as increasing
prevalence of sleep disorders and rising demand for effective
treatments. Current priorities include expanding clinical coverage
and addressing unmet needs in CNS stimulant therapies. Strategies
include collaborations, acquisitions, and product development to
maintain industry leadership.
Discover 360° analysis of this market. For complete information,
schedule your consultation - Book Here!
Market Challenges
- The Central Nervous System (CNS) stimulant drugs market
encompasses medications used to treat various neurological
conditions, such as Attention-Deficit Hyperactivity Disorder (ADHD)
and narcolepsy. Medications like methylphenidates (RITALIN,
Focalin, Metadate, CONCERTA) and amphetamines (DEXEDRINE, Adderall,
VYVANSE) are commonly used. While effective in managing symptoms,
these drugs come with potential side effects. Methylphenidates may
cause heart and liver damage, strokes, and epilepsy, among other
issues. Amphetamines, used for narcolepsy, can lead to brain injury
and neurotoxicity at high doses. Additionally, stimulants are
frequently abused, resulting in health risks such as cardiovascular
complications, seizures, and structural brain changes. Despite
these concerns, the improved efficacy of new treatments continues
to drive market growth.
- The Central Nervous System (CNS) Stimulant Drugs Market is
projected to experience significant growth in the coming years.
According to recent industry reports, the market is expected to
reach new heights, with financial projections indicating robust
growth trajectory. Success factors for market players include
meeting the needs of healthcare services, particularly in Child
& Adolescent Psychiatry, Sleep Apnea, and Narcolepsy. The
American Thoracic Society and Senior population are key priority
areas. Strategies for growth include inorganic growth through
acquisitions and partnerships with innovators like Independence
Pharmaceuticals. Country-level focus and cutting-edge research are
current priorities. Sleep Care Online is a growing sector, offering
opportunities for market expansion. Stay active in this dynamic
industry to stay ahead of the competition.
For more insights on driver and
challenges - Request a sample report!
Segment Overview
This central nervous system (cns) stimulant drugs market report
extensively covers market segmentation by
- Distribution Channel
- Application
- 2.1 Attention-deficit hyperactivity disorder
- 2.2 Narcolepsy
- 2.3 Others
- Geography
- 3.1 North America
- 3.2 Europe
- 3.3 Asia
- 3.4 Rest of World (ROW)
1.1 Hospitals- The Central Nervous System (CNS)
stimulant drugs market is driven by the increasing prevalence of
Attention-Deficit Hyperactivity Disorder (ADHD), a chronic brain
condition affecting development and functioning. ADHD is common in
children and adolescents worldwide, making stimulant therapy, the
first-line treatment, a significant market growth factor. The US
FDA has approved 29 stimulants in the US for ADHD treatment,
including Adhansia XR from Purdue Pharma and JORNAY PM, a new
methylphenidate formulation. The easy availability of these
medications will further accelerate market growth during the
forecast period.
For more information on market segmentation with geographical
analysis including forecast (2023-2027) and historic data
(2017-2021) - Download a Sample Report
Research Analysis
The Central Nervous System (CNS) stimulant drugs market is a
significant segment in the healthcare industry, primarily used for
treating various neurological and psychiatric conditions. These
drugs work by increasing the levels of dopamine and norepinephrine
in the brain, leading to improved focus, alertness, and energy. The
market for CNS stimulant drugs has been growing steadily due to the
increasing prevalence of conditions such as Attention Deficit
Hyperactivity Disorder (ADHD), Child & Adolescent Psychiatry,
Sleep apnea, and Narcolepsy. The American Thoracic Society reports
that sleep disorders affect millions of people worldwide, driving
demand for CNS stimulant drugs in Sleep Care Online and Hospital
settings. The senior population is another significant consumer
group, as CNS stimulant drugs are used to treat conditions like
Parkinson's disease and depression. The market projections indicate
a positive growth trajectory, with the increasing acceptance of
telemedicine and digital health solutions enabling wider access to
these drugs at the country level. Active ingredients such as
Methylphenidate and Amphetamines dominate the market, with various
formulations available in the form of tablets, capsules, and
injectables. The market is expected to remain active, driven by the
increasing demand for effective treatments for neurological and
psychiatric conditions.
Market Research Overview
The Central Nervous System (CNS) Stimulant Drugs Market is a
significant segment of the healthcare services industry, focusing
on the development and distribution of medications that enhance the
functioning of the central nervous system. These drugs are
primarily used in Child & Adolescent Psychiatry to treat
Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy. The
market also caters to other medical conditions like Sleep Apnea and
the growing senior population. The American Thoracic Society and
Sleep Care Online are key platforms driving market growth through
advocacy and telemedicine services. The market is projected to
experience robust growth due to increasing disease prevalence,
inorganic growth through acquisitions, and the innovator status of
new CNS stimulant drugs. The industry coverage includes both Active
Pharmaceutical Ingredients (APIs) and finished dosage forms. The
growth trajectory is influenced by financial details such as market
size, revenue, and profitability. Success factors include
regulatory approvals, strategic partnerships, and research &
development investments. Current priorities include addressing
unmet medical needs, expanding indications, and improving patient
outcomes. Strategies include product differentiation, geographical
expansion, and pricing strategies.
Table of Contents:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation
- Distribution Channel
-
- Application
-
- Attention-deficit Hyperactivity Disorder
- Narcolepsy
- Others
- Geography
-
- North America
- Europe
- Asia
- Rest Of World (ROW)
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix
About Technavio
Technavio is a leading global technology research and advisory
company. Their research and analysis focuses on emerging market
trends and provides actionable insights to help businesses identify
market opportunities and develop effective strategies to optimize
their market positions.
With over 500 specialized analysts, Technavio's report library
consists of more than 17,000 reports and counting, covering 800
technologies, spanning across 50 countries. Their client base
consists of enterprises of all sizes, including more than 100
Fortune 500 companies. This growing client base relies on
Technavio's comprehensive coverage, extensive research, and
actionable market insights to identify opportunities in existing
and potential markets and assess their competitive positions within
changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/central-nervous-system-cns-stimulant-drugs-market-size-is-set-to-grow-by-usd-6-48-billion-from-2023-2027--rise-in-incidence-of-cns-disorders-boost-the-market-technavio-302195567.html
SOURCE Technavio